0001562180-22-001412.txt : 20220211 0001562180-22-001412.hdr.sgml : 20220211 20220211163907 ACCESSION NUMBER: 0001562180-22-001412 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220209 FILED AS OF DATE: 20220211 DATE AS OF CHANGE: 20220211 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Jones David Scott CENTRAL INDEX KEY: 0001779458 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-51122 FILM NUMBER: 22621849 MAIL ADDRESS: STREET 1: C/O EYEPOINT PHARMACEUTICALS, INC., STREET 2: 480 PLEASANT STREET, SUITE A210 CITY: WATERTOWN STATE: MA ZIP: 02472 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: EyePoint Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001314102 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 262774444 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-926-5000 MAIL ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: pSivida Corp. DATE OF NAME CHANGE: 20080619 FORMER COMPANY: FORMER CONFORMED NAME: pSivida LTD DATE OF NAME CHANGE: 20050111 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2022-02-09 false 0001314102 EyePoint Pharmaceuticals, Inc. EYPT 0001779458 Jones David Scott C/O EYEPOINT PHARMACEUTICALS, INC. 480 PLEASANT STREET WATERTOWN MA 02472 false true false false SVP & Chief Commercial Officer Common Stock 2022-02-09 4 M false 4966.00 0.00 A 14097.00 D Common Stock 2022-02-09 4 F false 1473.00 10.13 D 12624.00 D Restricted Stock Units 0.00 2022-02-09 4 A false 15000.00 0.00 A Common Stock 15000.00 15000.00 D Restricted Stock Units 0.00 2022-02-09 4 M false 4966.00 0.00 D Common Stock 4966.00 9934.00 D Stock Option (Right to Buy) 10.13 2022-02-09 4 A false 60000.00 0.00 A 2032-02-09 Common Stock 60000.00 60000.00 D Includes 886 shares acquired on July 30, 2021 and 865 shares acquired on January 31,2022 pursuant to EyePoint's 2019 Employee Stock Purchase Plan. No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units The restricted stock units will vest in three ratable annual installments beginning February 9, 2023. The restricted stock units vest in three ratable annual installments beginning February 9, 2022. The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2023 and the remainder ratably, on a monthly basis, over the remaining three years. /s/ Ron Honig, Attorney-in-Fact 2022-02-11